Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-Donor Derived Probiotics for Intestinal aGVHD
NCT07188909Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of Golden Bifid in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Clinical response rate of intestinal acute graft-versus-host disease (aGVHD) at 100 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Golden Bifid
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07188909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188909.